Navigation Links
BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
Date:8/18/2008

Product Line Extension Builds on Existing Brand Strength and Pediatric

Focus

PLYMOUTH MEETING, Pa., Aug. 18 /Xinhua-PRNewswire-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP; "BMP Sunstone"; the ''Company'') today announced that the Sunstone (Tangshan) Pharmaceutical Co., Ltd. ("Sunstone"), its wholly-owned subsidiary, has received a production license from the Chinese State Food and Drug Administration ("SFDA") to manufacture and market GoodBaby Multivitamin Granules, a multivitamin formula for infants and children in China. The Company expects to launch the product at the end of the fourth quarter of 2008.

Mr. Zhiqiang Han, President and Chief Operating Officer of BMP Sunstone, commented, "We are excited about receiving the final approval from the SFDA to manufacture and market our multivitamin granule product. Pediatric multivitamins is an ideal extension of our GoodBaby brand as it builds on our existing brand strength and pediatric focus."

Mr. Han continued, "Demand for vitamin supplements is a substantial emerging market opportunity in China, where vitamin deficiency is common, especially in infants and children. We estimate that the market for pediatric vitamins can reach RMB 2 billion within the next 5 years at a sustainable annual growth rate of 15%. Parents in China are increasingly willing to pay a premium for high-quality branded children's products, resulting from the country's one-child policy. The approved product is developed to meet the special metabolic and nutritional requirements of Chinese children and is formulated with our pediatric expertise to cater to children's unique tastes. Special topic health seminars for children and their parents are expected to be part of our national launch plan starting the fourth quarter of 2008."

Mr. David Gao, Chief Executive Officer of BMP Sunstone, stated, "We expect quick turnaround in capturing market share with the launch of GoodBaby Multivitamin Granules, by utilizing our well established OTC sales and distribution network. Our vast knowledge and experience in the pediatric pharmaceutical market has helped us create an innovative formula which would enable us to become a market leader in this area. We are optimistic that this new product will provide an additional revenue stream for BMP Sunstone. Moving forward, we will continue leveraging our strong GoodBaby brand and marketing channels to extend our product portfolio through internal development efforts and external product acquisitions. Sunstone currently has a line of products under development or pending final approval from the SFDA. We remain committed to being the market leader in women's and children's health and, ultimately, to maximizing shareholder value."

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Currently this portfolio includes eight products under exclusive multi-year licenses for China, primarily focused on women's health and pediatrics. The Company also owns Sunstone Pharmaceutical Co. Ltd., which manufactures leading pediatric and women's health products, including two of China's most recognized brands, Hao Wawa(R) (GoodBaby) and Confort(TM), sold through approximately 50,000 pharmacies in China. The Company also provides pharmaceutical distribution services through its subsidiaries in Beijing and Shanghai, and through its affiliate, Guangzhou Pharmaceuticals Corp. The Company has its main office in Beijing, with a US office in Plymouth Meeting, PA. For more information, please visit http://www.bmpsunstone.com .

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about the expected launch date of the SFDA-approved multivitamin formula, the market for pediatric vitamins within the next 5 years at a sustainable annual growth rate of 15%, the turnaround in capturing market share, our ability to be a market leader in the pediatric pharmaceutical market, the SFDA-approved multivitamin formula providing an additional revenue stream for BMP Sunstone, the ability of the Company to leverage the GoodBaby brand and marketing channels to extend the Company's product portfolio through internal development efforts and external product acquisitions, the possible approval of additional products by the SFDA in the future, being the market leader in women's and children's health and maximizing shareholder value. . These statements are subject to uncertainties and risks including, but not limited to, our ability to successfully launch the SFDA-approved multivitamin formula, competitors in the multivitamin market, our ability to take advantage of synergies between our various subsidiaries and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

BMP Sunstone Corporation

Fred M. Powell

Chief Financial Officer

Tel: +1-610-940-1675

Integrated Corporate Relations, Inc.

Ashley Ammon MacFarlane and Christine Duan

Tel: +1-203-682-8200 (Investor Relations)


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BMP Sunstone Reports Second Quarter 2008 Financial Results
2. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
3. BMP Sunstone Receives Import Drug License (IDL) from SFDA
4. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
7. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
8. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
9. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
10. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
11. Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Oakland, California (PRWEB) , ... April 25, 2017 ... ... Artificial Intelligence (AI), leading supplier of Common Lisp (CL) development tools, and market ... 10.1 , which includes key performance enhancements now available within the most effective ...
(Date:4/25/2017)... SEATTLE, WA (PRWEB) , ... April 25, 2017 , ... ... technology division of Quorum, will be featured in multiple sessions at this week’s ... range from emerging trends to best practices in clinical research. , "We are excited ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, in ... to three startups through the UConn Innovation Fund. The $1.5 million UConn Innovation ... with UConn. , The UConn Innovation Fund provides investments of up to $100,000 ...
(Date:4/20/2017)... , ... April 20, 2017 , ... ... , this new webinar will explore challenging patient cases when screening for direct ... hospital, there may be a need for bridging parental anticoagulation especially for those ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):